Tubulin Inhibitor ALB 109564 Dihydrochloride

2020 ◽  
Author(s):  
Keyword(s):  
Tubulin Inhibitor

MPT0B169, a New Tubulin Inhibitor, Inhibits Cell Growth and Induces G2/M Arrest in Nonresistant and Paclitaxel-Resistant Cancer Cells

Pharmacology ◽  
2013 ◽  
Vol 92 (1-2) ◽  
pp. 90-98 ◽  
Author(s):  
Wei-Hwa Lee ◽  
Hsinjin Eugene Liu ◽  
Jang-Yang Chang ◽  
Jing-Ping Liou ◽  
Huei-Mei Huang
Keyword(s):  
Cell Growth ◽  
Cancer Cells ◽  
Tubulin Inhibitor

A novel tubulin inhibitor STK899704 induces tumor regression in DMBA/TPA-induced skin carcinogenesis model

2018 ◽  
Vol 27 (3) ◽  
pp. 285-288 ◽  
Author(s):  
Joonsung Hwang ◽  
Nak Kyun Soung ◽  
Ho Jin Han ◽  
Yongjun Lee ◽  
Tae Woong Choi ◽  
...  
Keyword(s):  
Tumor Regression ◽  
Skin Carcinogenesis ◽  
Tubulin Inhibitor

scholarly journals Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities

2018 ◽  
Vol 61 (17) ◽  
pp. 7877-7891 ◽  
Author(s):  
Qinghui Wang ◽  
Kinsie E. Arnst ◽  
Yuxi Wang ◽  
Gyanendra Kumar ◽  
Dejian Ma ◽  
...  
Keyword(s):  
Structural Modification ◽  
Tubulin Inhibitor ◽  
Antiproliferative Activities

The oral α and β tubulin inhibitor, VERU-111, for the treatment of metastatic castration-resistant and androgen blocking agent-resistant prostate cancer in nonclinical toxicity studies.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 299-299
Author(s):  
Robert H. Getzenberg ◽  
Mario A. Eisenberger ◽  
Mark Christopher Markowski ◽  
Gary Barnette ◽  
Darryl Patrick ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Liver Function ◽  
Liver Function Tests ◽  
Blocking Agent ◽  
Resistance Mechanisms ◽  
Multi Drug Resistance ◽  
High Dose ◽  
Tubulin Inhibitor ◽  
Toxicity Studies ◽  
Taxane Chemotherapy

299 Background: A dose limiting toxicity of taxane chemotherapy, including docetaxel and cabazitaxel, is neutropenia. VERU-111 is a novel, oral aand btubulin inhibitor that blocks tubulin polymerization and is not a substrate for multi-drug resistance mechanisms. Nonclinical toxicity studies were recently performed in order to assess the effects of daily, high-dose administration of orally dosed daily VERU-111. Methods: Toxicity of VERU-111 was evaluated in a 28-day oral dosing toxicity study which was conducted in both rats and dogs. These studies were performed at an independent facility under GLP conditions. Results: In both species evaluated, at oral doses of ≤3 mg/kg/day (rat) and ≤8 mg/kg/day (dog) there were no significant observed findings of neutropenia, myelosuppression, or abnormal liver function. Conclusions: In contrast to cabazitaxel and docetaxel, which are given once every 3 weeks IV, VERU-111 given oral, daily for 28 days in toxicity studies in dog and rat did not result in neutropenia, and myelosuppression. Furthermore, VERU-111 orally each day did not affect liver function tests. These nonclinical toxicity studies provide the basis for progressing VERU-111 into a Phase 1b/2 study which targets men with metastatic castration and androgen blocking agent (abiraterone and enzalutamide) resistant prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document